Yep agree. Also see my earlier post where I estimated an annualised NPAT to be approx $29m. Based on that the current PE is roughly 21, which is crazy for a global company growing at such a fast rate.
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market